Page last updated: 2024-12-07
vestitol
Description
Vestitol is a synthetic, non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities. It is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically COX-2, which are key mediators of inflammation. The compound's mechanism of action involves the inhibition of prostaglandin synthesis, thereby reducing inflammation and pain. Vestitol has been studied for its potential therapeutic use in various inflammatory conditions, including rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease. However, it has not yet been approved for clinical use, and further research is needed to evaluate its safety and efficacy in humans.'
vestitol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
vestitol : A member of the class of hydroxyisoflavans that is isoflavan substituted by hydroxy groups at positions 7 and 2' and a methoxy group at position 4'. Isolated from Glycyrrhiza uralensis, it exhibits anti-inflammatory activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Glycyrrhiza | genus | A genus of leguminous herbs or shrubs whose roots yield GLYCYRRHETINIC ACID and its derivative, CARBENOXOLONE.[MeSH] | Fabaceae | The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH] |
| Glycyrrhiza uralensis | species | A plant species of the family FABACEAE.[MeSH] | Fabaceae | The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH] |
| Glycyrrhiza uralensis | species | A plant species of the family FABACEAE.[MeSH] | Fabaceae | The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH] |
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 92503 |
| CHEBI ID | 69088 |
| SCHEMBL ID | 1850123 |
| MeSH ID | M0504330 |
Synonyms (31)
| Synonym |
|---|
| 56701-24-7 |
| MEGXP0_000408 |
| ACON1_000883 |
| vestitol |
| NCGC00169266-01 |
| BRD-A15543399-001-01-6 |
| 3-(2-hydroxy-4-methoxyphenyl)-3,4-dihydro-2h-chromen-7-ol |
| z244uvz669 , |
| (+-)-vestitol |
| 2h-1-benzopyran-7-ol, 3,4-dihydro-3-(2-hydroxy-4-methoxyphenyl)- |
| vestitol, (+/-)- |
| 3-(2-hydroxy-4-methoxy-phenyl)chroman-7-ol |
| unii-z244uvz669 |
| CHEBI:69088 |
| SCHEMBL1850123 |
| (+/-)-vestitol |
| XRVFNNUXNVWYTI-UHFFFAOYSA-N |
| 3-(2-hydroxy-4-methoxyphenyl)-7-chromanol # |
| 2',7-dihydroxy-4'-methoxyisoflavan |
| 3,4-dihydro-3-(2-hydroxy-4-methoxyphenyl)-2h-1-benzopyran-7-ol |
| AKOS028108537 |
| ()-vestitol |
| NCGC00169266-02 |
| FT-0727023 |
| Q27137428 |
| FS-8805 |
| 3-(2-hydroxy-4-methoxyphenyl)chroman-7-ol |
| dl-vestitol |
| (3r)-vestitol; (r)-(-)-vestitol; vestitol |
| B0005-190028 |
| DTXSID801178444 |
Research Excerpts
Overview
Vestitol is an isoflavonoid isolated from Brazilian red propolis with potential anti-inflammatory activity.
Treatment
| Excerpt | Reference | Relevance |
|---|
| "Pre-treatment with vestitol at 1, 3, or 10 mg/kg reduced LPS- or mBSA-induced neutrophil migration and the release of CXCL1/KC and CXCL2/MIP-2 in vivo." | ( Vestitol Isolated from Brazilian Red Propolis Inhibits Neutrophils Migration in the Inflammatory Process: Elucidation of the Mechanism of Action.
Alencar, SM; Bueno-Silva, B; Castanheira, FV; Cólon, DF; Cunha, TM; da Cunha, MG; Franchin, M; Rosalen, PL, 2016) | 2.2 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Roles (3)
| Role | Description |
|---|
| anti-inflammatory agent | Any compound that has anti-inflammatory effects. |
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| phytoalexin | A toxin made by a plant that acts against an organism attacking it. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
| Class | Description |
|---|
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| hydroxyisoflavans | A member of the class of isoflavans in which one or more ring hydrogens are replaced by hydroxy groups. |
| methoxyisoflavan | Any member of the class of isoflavans in which one or more ring hydrogens are replaced by methoxy groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (16)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 23.93
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 23.93 (24.57) | | Research Supply Index | 2.83 (2.92) | | Research Growth Index | 5.12 (4.65) | | Search Engine Demand Index | 23.28 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |